PRC
PTCT icon

Pearl River Capital’s PTC Therapeutics PTCT Stock Holding History

Pearl River Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,832
Closed -$209K – 293
2024
Q2 		$209K Buy
+6,832
New +$221K 0.03% 394
2020
Q1 		– Sell
-6,714
Closed -$322K – 682
2019
Q4 		$322K Buy
+6,714
New +$285K 0.12% 319
2019
Q1 		– Sell
-400
Closed -$14K – 687
2018
Q4 		$14K Buy
+400
New +$14.4K 0.06% 423

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pearl River Capital's PTCT Position: Q3 2024 in Review

Pearl River Capital sold out of PTC Therapeutics (PTCT) in Q3 2024, closing a stake of 6,832 shares — an estimated $209K sold.

Pearl River Capital first reported a position in PTCT in Q4 2018 and held it in 3 quarters. The position peaked at $322K in Q4 2019. 202 funds tracked by Wall St. Rank hold PTCT as of Q3 2024.

  • Pearl River Capital reported no remaining PTC Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pearl River Capital sold 6,832 PTC Therapeutics shares in Q3 2024, an estimated $209K.
  • Pearl River Capital first reported a position in PTC Therapeutics in Q4 2018 and held it in 3 quarters.
  • Pearl River Capital's PTC Therapeutics position peaked at $322K in Q4 2019.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.